Pharma C Investments (AQSE: PCIL), an early-stage investor and venture builder in the medical cannabis industry with a particular focus on ancillary businesses, is pleased to announce that it has completed its first investment in a company called Product Earth Expo UK Limited (“Product Earth”).
Product Earth is the UK’s leading hemp and CBD trade show and exposition (“expo”). The event showcases cannabis-related businesses from the agricultural, industrial and medicinal, to production, wholesale and retail sectors. Product Earth also offers its customers a bespoke digital marketing service, providing support and expertise in showcasing their companies to a growing audience.
- Pharma C is investing £275,000 for 7.5% of the enlarged share capital of Product Earth, valuing Product Earth at £3.68m
- Product Earth held its first event in 2015 and despite the ban on public events in 2020, hosted a successful, profitable event in August 2021 at the National Agricultural Exhibition Centre
- In response to the pandemic, Product Earth built a digital marketing agency for hemp and cannabis-related businesses
- Product Earth is led by entrepreneurs with deep expertise in cannabis, media, and technology
- Product Earth has the ability and scope to expand its events and services into Europe and beyond
Product Earth is currently supporting the COP26 fringe event, Beyond the Green, in Glasgow which is running from 5th – 7th November. The event promotes the need to put the use of hemp high up on the climate agenda, due to its potential to decarbonise multiple industries and combat climate change through carbon capture. The event also looks at the medicinal benefits, job creation and health benefits the cannabis plant can provide.
Find out more at www.productearthexpo.com/
Sharon Segal, Chair of Pharma C Investments, said: “This is a major first step for Pharma C and we are delighted to have made our first investment in Product Earth. This investment exemplifies our focus on the non-plant touching, ancillary sector which support the growth of the medical cannabis industry and demonstrates that our proprietary pipeline delivers unique investment opportunities.”
“Product Earth has a special place in the UK cannabis industry as the first medical cannabis, CBD and hemp trade show. Product Earth has also developed digital marketing capabilities to support clients with broader brand building; its high-quality management team has decades of experience from the likes of Facebook and Yahoo. We look forward to working alongside the Product Earth team to support the business as it builds upon its foundations and looks towards global expansion.”
Tom Toumazis, MBE, Chair of Product Earth, said: “Product Earth is entering an exciting chapter as we service a rapidly growing sector in the UK. Hosting an event in 2021 came with its challenges but we still managed to make it a successful and profitable experience. Our digital marketing service is unrivalled within the cannabis industry, and we are proud to be helping exciting and interesting businesses grow.
“I am looking forward to working with Pharma C and utilising the expertise provided by the Board and management team. At Product Earth, we are committed to providing a world-class event for our customers and their clients, as well as expanding our digital marketing service to offer a range of products for a growing audience. Product Earth is also looking at taking its event to more countries around the world, enabling customers, businesses, patients and experts to connect on a global scale.”
Related Party Transaction
Gavin Sathianathan, Investment Strategy Director of Pharma C, is a director and shareholder of Product Earth and the investment is therefore a related party transaction in accordance with Rule 4.6 of the AQSE Growth Market Access Rulebook.
The Directors of Pharma C Investments plc take responsibility for this announcement.
This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).
As at 31 October 2021, Pharma C had cash balances of £607,870.